Erlotinib 100 Tab

<ul> <li style=\"text-align: left;\">Store the product at a temperature of less than 30 ° C.</li> <li style=\"text-align: left;\">Store the product away from moisture and light.</li> <li style=\"text-align: left;\">Keep the product out of the reach of children.</li> </ul>

<p dir=\"ltr\" style=\"text-align: left;\">Contact a poison control center.</p>

<ul> <li dir=\"ltr\" style=\"text-align: left;\">Interstitial Lung Disease (ILD) </li> <li dir=\"ltr\" style=\"text-align: left;\">Renal Failure </li> <li dir=\"ltr\" style=\"text-align: left;\">Hepatotoxicity with or without Hepatic Impairment </li> <li dir=\"ltr\" style=\"text-align: left;\">Gastrointestinal Perforation </li> <li dir=\"ltr\" style=\"text-align: left;\">Bullous and Exfoliative Skin Disorders </li> <li dir=\"ltr\" style=\"text-align: left;\">Cerebrovascular Accident </li> <li dir=\"ltr\" style=\"text-align: left;\">Microangiopathic Hemolytic Anemia with Thrombocytopenia ]</li> <li dir=\"ltr\" style=\"text-align: left;\">Ocular Disorders </li> <li dir=\"ltr\" style=\"text-align: left;\">Hemorrhage in Patients Taking Warfarin </li> </ul>

<ul> <li dir=\"ltr\" style=\"text-align: left;\">Co-administration of erlotinib with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor increased erlotinib exposure and may increase the risk of exposure-related toxicity  e.g. .boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole</li> <li dir=\"ltr\" style=\"text-align: left;\">Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure e.g., carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital </li> <li dir=\"ltr\" style=\"text-align: left;\">Co-administration of erlotinib with proton pump inhibitors (e.g., omeprazole) and H-2 receptor antagonists (e.g., ranitidine) decreased erlotinib exposure </li> <li dir=\"ltr\" style=\"text-align: left;\">interaction with coumarin-derived anticoagulants, including warfarin, leading to increased International Normalized Ratio (INR) and bleeding adverse reactions</li> </ul>

<p style=\"text-align: left;\">   Because of the potential for serious adverse reactions in breastfed infants from erlotinib, including interstitial lung disease, hepatotoxicity, bullous and exfoliative skin disorders, microangiopathic hemolytic anemia with thrombocytopenia, ocular disorders, and diarrhea. Advise a lactating woman not to breastfeed during treatment with erlotinib and for 2 weeks after the final dose</p>

<p style=\"text-align: left;\">FDA pregnancy category D.</p>

<ul> <li dir=\"ltr\" style=\"text-align: left;\">Erlotinib tablet is not recommended for use in combination with platinum-based chemotherapy</li> <li dir=\"ltr\" style=\"text-align: left;\">Safety and efficacy of Erlotinib Tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations</li> <li dir=\"ltr\" style=\"text-align: left;\"> Interstitial Lung Disease (ILD)</li> <li dir=\"ltr\" style=\"text-align: left;\">Renal Failure</li> <li dir=\"ltr\" style=\"text-align: left;\">Hepatotoxicity with or without Hepatic Impairment</li> </ul>

<p style=\"text-align: left;\">   People who have symptoms of allergy to this drug</p>

<ul> <li dir=\"ltr\" style=\"text-align: left;\">The recommended daily dose of Erlotinib Tablets for NSCLC is 150 mg taken on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food Treatment should continue until disease progression or unacceptable toxicity occurs.</li> <li dir=\"ltr\" style=\"text-align: left;\">The recommended daily dose of Erlotinib Tablets for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine </li> <li dir=\"ltr\" style=\"text-align: left;\">The safety and effectiveness of erlotinib in pediatric patients have not been established</li> <li dir=\"ltr\" style=\"text-align: left;\">No overall differences in safety or efficacy were observed between subjects 65 years and older and those younger than 65</li> </ul>

<ul> <li dir=\"ltr\" style=\"text-align: left;\">The treatment of patients with metastatic non-small cell lung cancer (NSCLC) </li> <li dir=\"ltr\" style=\"text-align: left;\">Erlotinib tablet in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer</li> </ul>

<p dir=\"ltr\">inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR)</p>